Oncocyte Corporation, a leading diagnostic technology company specializing in early cancer detection, recently announced its definitive agreement to acquire Razor Genomics, a privately held company focused on developing advanced bioinformatics solutions for precision medicine. The move is expected to strengthen Oncocyte`s position in the rapidly expanding field of precision medicine and enable it to offer a comprehensive suite of diagnostic and prognostic tools to better serve patients.

The acquisition of Razor Genomics will bring together two companies at the forefront of the fight against cancer. Oncocyte`s proprietary tests are designed to detect molecular changes in blood samples that can signify the presence of cancer, while Razor Genomics specializes in developing advanced algorithms and bioinformatics tools that can help identify genetic mutations and other biomarkers associated with cancer.

With the addition of Razor Genomics, Oncocyte will have access to a suite of advanced bioinformatics tools that will help it to further improve the accuracy and speed of its tests. These tools will also enable the company to better tailor its tests to individual patients, taking into account their unique genetic makeup and other factors that may influence their risk of developing cancer.

In addition to its advanced bioinformatics solutions, Razor Genomics also brings a wealth of expertise in the development of targeted therapies for cancer. By combining this expertise with Oncocyte`s diagnostic capabilities, the two companies hope to accelerate the development of personalized treatment regimens that are tailored to the specific needs of individual patients.

The acquisition of Razor Genomics is expected to close in the third quarter of 2021, pending regulatory approval. Once completed, the combined entity will be well-positioned to lead the way in the rapidly evolving field of precision medicine, offering patients and healthcare providers a comprehensive suite of diagnostic and prognostic tools that can help to detect cancer at its earliest stages and tailor treatment regimens to individual patients.

Overall, the acquisition of Razor Genomics by Oncocyte Corporation represents a significant step forward in the fight against cancer. By combining their respective areas of expertise, the two companies are poised to make major advances in the development of personalized, targeted therapies that can help to improve patient outcomes and reduce the burden of this deadly disease on patients and their families.